For the tens of millions of people living with HIV worldwide, the promise of a once-weekly oral pill — rather than daily dosing — represents a meaningful quality-of-life shift. A new pharmacokinetic study brings that prospect closer by confirming that combining two mechanistically distinct antiretrovirals into a single tablet does not substantially alter how the body absorbs or processes either drug.
The phase 1 open-label trial enrolled 93 HIV-negative adults and compared the pharmacokinetics of a fixed-dose combination (FDC) tablet containing islatravir 2 mg (a nucleoside reverse transcriptase translocation inhibitor, or NRTTI) and lenacapavir 300 mg (a first-in-class capsid inhibitor) against co-administration of the two drugs as separate agents under fasted conditions. For lenacapavir, overall exposure (AUCinf) in the FDC was 90.2% of the separate-agent reference — well within conventional bioequivalence boundaries — and peak concentration (Cmax) was essentially unchanged at 103%. Islatravir showed equivalent total exposure (AUCinf ratio 107%) but a notable 36% reduction in peak concentration within the FDC formulation. Regarding food effects, islatravir pharmacokinetics were unaffected by meals, while lenacapavir exposure increased with food intake, consistent with its established lipophilic absorption profile.
This trial is primarily a formulation feasibility study rather than an efficacy or safety milestone, and the 93-participant, HIV-negative cohort means real-world tolerability and viral suppression outcomes remain to be demonstrated in larger, longer trials. The 36% Cmax reduction for islatravir in the FDC deserves close attention: peak concentration differences can influence both efficacy thresholds and adverse-effect profiles, even when total drug exposure is preserved. Lenacapavir's known food-dependent absorption also means dietary consistency may matter for optimizing weekly dosing. Taken together, the data are encouraging for formulation viability but represent an incremental pharmacokinetic step. The combination strategy — pairing an NRTTI with a capsid inhibitor — targets two distinct points in the HIV replication cycle, which is scientifically rational for a simplified weekly regimen. Phase 2/3 efficacy trials will be the true test.